Remodeling and spacing factor 1 overexpression is associated with poor prognosis in renal cell carcinoma

Zhang,Xiuwei; Xue,Dongwei; Hao,Fengxia; Xie,Lingling; He,Jiani; Gai,Junda; Liu,Yuhui; Xu,Hongtao; Li,Qingchang; Wang,Enhua

doi:10.3892/ol.2018.7797

Remodeling and spacing factor 1 overexpression is associated with poor prognosis in renal cell carcinoma

Authors:
- Xiuwei Zhang
- Dongwei Xue
- Fengxia Hao
- Lingling Xie
- Jiani He
- Junda Gai
- Yuhui Liu
- Hongtao Xu
- Qingchang Li
- Enhua Wang
View Affiliations

Affiliations: Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Urology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning 110032, P.R. China
Published online on: January 15, 2018 https://doi.org/10.3892/ol.2018.7797
Pages: 3852-3857

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to assess the expression and prognostic significance of remodeling and spacing factor 1 (RSF1; HBXAP) in renal cell carcinoma (RCC). RSF1 expression was analyzed using immunohistochemistry on tissue samples from a consecutive series of 137 patients with RCC who underwent tumor resection between November 2000 and March 2004. The associations between RSF1 expression, clinicopathological factors and patient survival were investigated. Immunohistochemistry revealed that RSF1 was highly expressed in 43.1% (59/137) of the RCC samples. RSF1 expression levels were associated with the T stage of the Tumor‑Node‑Metastasis grading system. Kaplan‑Meier survival analysis indicated that high RSF1 expression in RCC was significantly associated with a poor prognosis. Multivariate analysis revealed that RSF1 expression is an independent prognostic parameter for the duration of overall survival of patients with RCC. The results demonstrated that a high expression level of RSF1 in RCC is associated with advanced tumor stages and a poor prognosis. To the best of our knowledge, the present study provides novel evidence of the biological significance of RSF1 expression in RCC.

View Figures

View References

1	Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
2	Gupta K, Miller JD, Li JZ, Russell MW and Charbonneau C: Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev. 34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
3	Hollingsworth JM, Miller DC, Daignault S and Hollenbeck BK: Five-year survival after surgical treatment for kidney cancer: A population-based competing risk analysis. Cancer. 109:1763–1768. 2007. View Article : Google Scholar : PubMed/NCBI
4	Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
5	LeRoy G, Orphanides G, Lane WS and Reinberg D: Requirement of RSF and FACT for transcription of chromatin templates in vitro. Science. 282:1900–1904. 1998. View Article : Google Scholar : PubMed/NCBI
6	Loyola A, Huang JY, LeRoy G, Hu S, Wang YH, Donnelly RJ, Lane WS, Lee SC and Reinberg D: Functional analysis of the subunits of the chromatin assembly factor RSF. Mol Cell Biol. 23:6759–6768. 2003. View Article : Google Scholar : PubMed/NCBI
7	Ho L and Crabtree GR: Chromatin remodelling during development. Nature. 463:474–484. 2010. View Article : Google Scholar : PubMed/NCBI
8	Mao TL, Hsu CY, Yen MJ, Gilks B, Sheu JJ, Gabrielson E, Vang R, Cope L, Kurman RJ, Wang TL and Shih IeM: Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. Hum Pathol. 37:1169–1175. 2006. View Article : Google Scholar : PubMed/NCBI
9	Yang YI, Ahn JH, Lee KT, Shih IeM and Choi JH: RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance. Cancer Res. 74:2258–2269. 2014. View Article : Google Scholar : PubMed/NCBI
10	Zhao XC, An P, Wu XY, Zhang LM, Long B, Tian Y, Chi XY and Tong DY: Overexpression of hSNF2H in glioma promotes cell proliferation, invasion, and chemoresistance through its interaction with Rsf-1. Tumour Biol. 37:7203–7212. 2016. View Article : Google Scholar : PubMed/NCBI
11	Sanchez-Garcia F, Villagrasa P, Matsui J, Kotliar D, Castro V, Akavia UD, Chen BJ, Saucedo-Cuevas L, Barrueco Rodriguez R, Llobet-Navas D, et al: Integration of genomic data enables selective discovery of breast cancer drivers. Cell. 159:1461–1475. 2014. View Article : Google Scholar : PubMed/NCBI
12	Cheng CK, Chow LW, Loo WT, Chan TK and Chan V: The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer. Cancer Res. 65:8646–8654. 2005. View Article : Google Scholar : PubMed/NCBI
13	Fang FM, Li CF, Huang HY, Lai MT, Chen CM, Chiu IW, Wang TL, Tsai FJ, Shih IeM and Sheu JJ: Overexpression of a chromatin remodeling factor, RSF-1/HBXAP, correlates with aggressive oral squamous cell carcinoma. Am J Pathol. 178:2407–2415. 2011. View Article : Google Scholar : PubMed/NCBI
14	Zhang X, Fu L, Xue D, Zhang X, Hao F, Xie L, He J, Gai J, Liu Y, Xu H, et al: Overexpression of Rsf-1 correlates with poor survival and promotes invasion in non-small cell lung cancer. Virchows Arch. 470:553–560. 2017. View Article : Google Scholar : PubMed/NCBI
15	Shih IeM, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE, Vang R, Parmigiani G, Kurman RJ, Trope CG, et al: Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci USA. 102:14004–14009. 2005. View Article : Google Scholar : PubMed/NCBI
16	Li Q, Dong Q and Wang E: Rsf-1 is overexpressed in non-small cell lung cancers and regulates cyclinD1 expression and ERK activity. Biochem Biophys Res Commun. 420:6–10. 2012. View Article : Google Scholar : PubMed/NCBI
17	Li H, Zhang Y, Zhang Y, Bai X, Peng Y and He P: Rsf-1 overexpression in human prostate cancer, implication as a prognostic marker. Tumour Biol. 35:5771–5776. 2014. View Article : Google Scholar : PubMed/NCBI
18	Xie C, Fu L, Xie L, Liu N and Li Q: Rsf-1 overexpression serves as a prognostic marker in human hepatocellular carcinoma. Tumour Biol. 35:7595–7601. 2014. View Article : Google Scholar : PubMed/NCBI
19	O'Sullivan GC, Tangney M, Casey G, Ambrose M, Houston A and Barry OP: Modulation of p21-activated kinase 1 alters the behavior of renal cell carcinoma. Int J Cancer. 121:1930–1940. 2007. View Article : Google Scholar : PubMed/NCBI
20	Meng ZW, Pan W, Hong HJ, Chen JZ and Chen YL: Modified staging classification for intrahepatic cholangiocarcinoma based on the sixth and seventh editions of the AJCC/UICC TNM staging systems. Medicine (Baltimore). 96:e78912017. View Article : Google Scholar : PubMed/NCBI
21	Davidson B, Trope' CG, Wang TL and Shih IeM: Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Gynecol Oncol. 103:814–819. 2006. View Article : Google Scholar : PubMed/NCBI
22	Roberts CW and Orkin SH: The SWI/SNF complex-chromatin and cancer. Nat Rev Cancer. 4:133–142. 2004. View Article : Google Scholar : PubMed/NCBI
23	Choi JH, Sheu JJ, Guan B, Jinawath N, Markowski P, Wang TL and Shih IeM: Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res. 69:1407–1415. 2009. View Article : Google Scholar : PubMed/NCBI
24	Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, et al: Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol. 100:264–270. 2006. View Article : Google Scholar : PubMed/NCBI
25	Hennessy BT, Nanjundan M, Cheng KW, Nolden L and Mills GB: Identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in ovarian cancer. Eur J Hum Genet. 14:381–383. 2006. View Article : Google Scholar : PubMed/NCBI
26	Bostner J, Ahnström WM, Fornander T, Skoog L, Nordenskjöld B and Stål O: Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene. 26:6997–7005. 2007. View Article : Google Scholar : PubMed/NCBI
27	Borg A, Tandon AK, Sigurdsson H, Clark GM, Fernö M, Fuqua SA, Killander D and McGuire WL: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 50:4332–4337. 1990.PubMed/NCBI
28	Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, Chastagner P, Baranzelli MC, Plantaz D, Avet-Loiseau H, Bénard J, et al: N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique. J Clin Oncol. 15:1171–1182. 1997. View Article : Google Scholar : PubMed/NCBI
29	Shamay M, Barak O and Shaul Y: HBXAP, a novel PHD-finger protein, possesses transcription repression activity. Genomics. 79:523–529. 2002. View Article : Google Scholar : PubMed/NCBI
30	Sheu JJ, Choi JH, Guan B, Tsai FJ, Hua CH, Lai MT, Wang TL and Shih IeM: Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development. J Pathol. 229:559–568. 2013. View Article : Google Scholar : PubMed/NCBI